VivoSeq
Oncology

Rectal Cancer

6

Pipeline Programs↗

33

Active Trials↗

12

Companies Involved↗

Rectal Cancer is an early-stage landscape with 6 programs across 12 companies. The most active players are Roche, Essen Biotech, BeiGene. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

39/100

Mech. Concentration

33/100

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2E

Essen Biotech

1 program

Phase 2BeiGene logo

BeiGene

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2Teva logo

Teva

1 program

Phase 3Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody229%
Protein / enzyme114%

Modality classified for 88% of 8 pipeline programs.

Analysis

Trial Status

102

clinical trials

Completed42 · 41%
Recruiting18 · 18%
Unknown status13 · 13%
Terminated8 · 8%
Not yet recruiting8 · 8%
Active, not recruiting6 · 6%
Other7 · 7%

Clinical Trials

Trial Activity

102 trials

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
Recruiting·UUniversity Hospital, Geneva·Phase 2·NCT04109755·25 enrolled
Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer
Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT07068763·52 enrolled
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT05972655·32 enrolled
Contact Radiotherapy for Rectal Cancer
Recruiting·—·N/A·NCT06501053·110 enrolled
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
Recruiting·FFudan University·Phase 3·NCT05201430·300 enrolled
Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
Recruiting·JJinhua Central Hospital·Phase 2·NCT06204094·37 enrolled
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05672524·37 enrolled
A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07347951·30 enrolled
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
Recruiting·—·Phase 2·NCT03714490·200 enrolled
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Recruiting·OOhio State University Comprehensive Cancer Center·Phase 2·NCT07407647·25 enrolled
To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer
Recruiting·—·Phase 2·NCT06808412·118 enrolled
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03875781·540 enrolled
Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer
Recruiting·HHelsinki University Central Hospital·N/A·NCT04842006·93 enrolled
Neoadjuvant Regorafenib in Combination with Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
Recruiting·JJules Bordet Institute·Phase 2·NCT04503694·72 enrolled
Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial
Recruiting·CColospan Ltd.·Preclinical·NCT04184973·250 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)